Search Results - "BLOEMENDAL, H"

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective by de Joode, K., Dumoulin, D.W., Engelen, V., Bloemendal, H.J., Verheij, M., van Laarhoven, H.W.M., Dingemans, I.H., Dingemans, A.C., van der Veldt, A.A.M.

“…The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care of…”
Get full text

Prospective experimental treatment of colorectal cancer patients based on organoid drug responses by Ooft, S.N., Weeber, F., Schipper, L., Dijkstra, K.K., McLean, C.M., Kaing, S., van de Haar, J., Prevoo, W., van Werkhoven, E., Snaebjornsson, P., Hoes, L.R., Chalabi, M., van der Velden, D., van Leerdam, M., Boot, H., Grootscholten, C., Huitema, A.D.R., Bloemendal, H.J., Cuppen, E., Voest, E.E.

“…Organoid technology has recently emerged as a powerful tool to assess drug sensitivity of individual patient tumors in vitro. Organoids may therefore represent…”
Get full text

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial by Bamias, A., Gibbs, E., Khoon Lee, C., Davies, L., Dimopoulos, M., Zagouri, F., Veillard, A.-S., Kosse, J., Santaballa, A., Mirza, M.R., Tabaro, G., Vergote, I., Bloemendal, H., Lykka, M., Floquet, A., Gebski, V., Pujade-Lauraine, E.

“…In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved…”
Get full text

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT) by Ubink, I, Bloemendal, H J, Elias, S G, Brink, M A, Schwartz, M P, Holierhoek, Y C W, Verheijen, P M, Boerman, A W, Mathijssen, R H J, de Leng, W W J, de Weger, R A, van Grevenstein, W M U, Koopman, M, Lolkema, M P, Kranenburg, O, Borel Rinkes, I H M

“…The identification of four Consensus Molecular Subtypes (CMS1-4) of colorectal cancer forms a new paradigm for the design and evaluation of subtype-directed…”
Get full text

ReCab II: A phase II trial of Cabazitaxel +/- Rhenium -188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment by Bouman-Wammes, E., van Dodewaard-De Jong, J.M., Bloemendal, H., Verheul, H.M., de Klerk, J.M.H., van den Eertwegh, A.J.M.

Get full text

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer by Janssen, A, Verkleij, C P M, van der Vlist, A, Mathijssen, R H J, Bloemendal, H J, ter Heine, R

“…Background: Cabazitaxel is approved for treatment of castration-resistant metastatic prostate cancer. The current dosing strategy of cabazitaxel is based on…”
Get full text

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs by Overbeek, J.K., ter Heine, R., Verheul, H.M.W., Chatelut, E., Rudek, M.A., Gurney, H., Plummer, R., Gilbert, D.C., Buclin, T., Burger, D.M., Bloemendal, H.J., van Erp, N.P.

Get full text

Severe hypertriglyceridaemia associated with the use of capecitabine by POLINDER-BOS, H. A, KOK, E. E, VAN DE WIEL, A, SPIERING, W, WIELDERS, J. P. M, BLOEMENDAL, H. J

Get full text

Structural and functional similarities of bovine alpha-crystallin and mouse small heat-shock protein. A family of chaperones by MERCK, K. B, GROENEN, P. J. T. A, VOORTER, C. E. M, DE HAARD-HOEKMAN, W. A, HORWITZ, J, BLOEMENDAL, H, DE JONG, W. W

“…alpha-Crystallin, composed of the subunits alpha A and alpha B, is a major vertebrate eye lens protein, accomplishing a structural role in maintaining lens…”
Get full text

New strategies in anti-vascular cancer therapy by BLOEMENDAL, H. J, LOGTENBERG, T, VOEST, E. E

“…Angiogenesis is a critical step in the progression of tumours from dormancy to a clinical relevant cancer. Inhibition of this process is one of the most…”
Get full text

Disorganization of membranes and abnormal intermediate filament assembly lead to cataract by BLOEMENDAL, H

Get full text

Alpha-B-crystallin in neuropathology by van Rijk, A F, Bloemendal, H

“…alphaB-Crystallin, which has homology with the small heat shock proteins, is the basic subunit of alpha-crystallin, a major component of the vertebrate eye…”
Get more information

1312O From regulating off-label use to creating an environment for drug repurposing in oncology by van Waalwijk van Doorn-Khosrovani, S., Pisters, A., Breugel, E., Timmers, L., Voest, E.E., Bloemendal, H., Eskens, F.A., Wymenga, M.

Get full text

Assembly of connexins and MP26 in lens fiber plasma membranes studied by SDS-fracture immunolabeling by Dunia, I, Recouvreur, M, Nicolas, P, Kumar, N, Bloemendal, H, Benedetti, E L

“…The SDS-fracture immunolabeling technique, unlike conventional freeze-fracture, provides direct evidence for the biochemical nature of membrane constituents…”
Get full text

Structure and assembly of the 20S proteasome by Gerards, W. L. H, de Jong, W. W, Boelens, W, Bloemendal, H

“…The barrel-shaped 20S proteasome is one of the two components of a larger 26S particle, the multicatalytic 2000-kDa protease complex. The proteolytic sites are…”
Get full text

In vitro filament-like formation upon interaction between lens α-crystallin and βL-crystallin promoted by stress by WEINREB, Orly, VAN RIJK, Anke F, DOVRAT, Ahuva, BLOEMENDAL, Hans

Get full text

1391P Tumor-first mutation-specific risk approach to trigger germline testing in castration-resistant prostate cancer by Kloots, I.S.H., Kets, M., Schuurs-Hoeijmakers, J., Westdorp, H., Coskunturk, M., Bloemendal, H., Gerritsen, W.R., van Oort, I.M., Ligtenberg, M., Mehra, N.

Get full text

769P Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study by Overbeek, J., Guchelaar, N., Mohmaed Ali, M.I., Ottevanger, P.B., Bloemendal, H., Koolen, S., Mathijssen, R., Boere, I., Hamberg, P., Huitema, A., Sonke, G., Opdam, F., Ter Heine, R., Van Erp, N.

Get full text

1563P Tumor-intrinsic subtypes of esophageal adenocarcinoma associate cellular phenotypes with responses to therapy by Blangé, D., Dings, M., van der Zalm, A., Lansbergen, M., Verzaal, M., Oyarce, C., Meijer, S., Waasdorp, C., van Mourik, M., Longobardi, C., Cuppen, E., Bloemendal, H., Koster, J., Zwijnenbrug, D., Medema, J-P., van Laarhoven, H.W.M., Bijlsma, M.F.

Get full text

1710P Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP) by Zeverijn, L.J., van Berge Henegouwen, J.M., Geurts, B.S., de Wit, G.F., Hoes, L., van der Wijngaart, H., van der Noort, V., Huitema, A.D.R., De Vos, F.Y.F.L., Grunberg, K., Bloemendal, H., Verheul, H.M.W., Voest, E.E., Gelderblom, H.

Get full text